Collaboration revenue fell 61% from a year ago as Roche deferred revenue winds down, missing expectations, and the earnings beat rests on a non-cash warrant gain. The NeuroAirmid deal closing adds Huntington's cell therapy HUNT1 as a third clinical asset, with $45.2 million in cash funding operations into Q2 2028.
Lineage Cell Therapeutics Inc
LCTX at a Glance
- Market cap
- $206.4M
- Revenue (TTM)
- $10.8M
- Profit margin
- 16.2%
- EPS (TTM)
- $-0.09
- 52-week range
- $1 – $2
- Street target
- $5.50
Headquartered in Carlsbad, CA Fiscal year ends December NYSE MKT: LCTX lineagecell.com
About Lineage Cell Therapeutics
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing allogeneic, "off-the-shelf" cell transplant therapies for serious medical conditions. Its programs are built on its proprietary AlloSCOPE cell manufacturing platform, which includes the patented AlloSCOPE "5D" technology combining 2D-like growth control with 3D bioreactor scale. With this platform, Lineage differentiates established pluripotent cell lines into specialized human cells that are transplanted to replace or support absent or dysfunctional cells.
The pipeline includes:
- OpRegen (RG6501), a retinal pigment epithelial cell therapy for geographic atrophy secondary to dry AMD, in Phase 2a under a worldwide collaboration with Roche and Genentech.
- HUNT1, a neural cell therapy for Huntington's Disease in the Phase 1b/2a REGEN4HD study, acquired through the November 2026 purchase of NeuroAirmid Therapeutics.
- OPC1, an oligodendrocyte progenitor cell therapy for spinal cord injury, in the DOSED device study.
- COR1, a preclinical corneal endothelial cell therapy for Fuchs dystrophy and bullous keratopathy.
- ReSonance (ANP1), an auditory neuron therapy for hearing loss, developed with William Demant Invest.
- ILT1, an islet cell manufacturing initiative for Type 1 Diabetes.
- RND1, a hypoimmune iPSC line.
- PNC1, a photoreceptor research initiative.
Revenue comes mainly from collaboration revenue, including deferred revenue from the Roche agreement and the WDI collaboration, along with royalties and license fees. Cell banking and manufacturing are conducted by its subsidiary in Jerusalem, Israel. Updated
Frequently Asked Questions
What does Lineage Cell Therapeutics do?
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing allogeneic, "off-the-shelf" cell transplant therapies for serious medical conditions.
What is the LCTX stock price target?
The Wall Street consensus 12-month price target for LCTX is $5.50.